The next generation of imaging technology, newly installed at the University of Cambridge, will give researchers an unprecedented view of the human body – in particular of the myriad connections within our brains and of tumours as they grow and respond to treatment – and could pave the way for development of treatments personalised for individual patients.
Researchers have identified the role that a four-stranded version of DNA may play in the role of cancer progression, and suggest that it may be used to develop new targeted cancer therapies.
Scientists have unearthed crucial new genetic information about how breast cancer develops and the genetic changes which can be linked to survival, according to a study published in Nature Communications today.
The University of Cambridge has received an additional £5 million over two years from Cancer Research UK for the launch of a ‘Major Centre’, focused on integrative cancer medicine and early detection.
A rare DNA base, previously thought to be a temporary modification, has been shown to be stable in mammalian DNA, suggesting that it plays a key role in cellular function.
A test for a wide range of genetic risk factors could improve doctors’ ability to work out which women are at increased risk of developing breast cancer, a major study of more than 65,000 women has shown.
One of the world’s leading childhood brain tumour experts, Professor Richard Gilbertson, has been appointed as Li Ka Shing Chair of Oncology in Cambridge and Director of the Cambridge Cancer Centre. He will take up his appointment in August.